Business context and reporting period
Important identification note: The supplied filing is Social Capital Suvretta Holdings Corp. III’s Form 10-Q, not a ProKidney Corp. filing. It covers the quarter ended September 30, 2021; the company was a newly formed SPAC and had not commenced operating activities. It intended to seek a business combination, with a focus on biotechnology and the organ subsector. The filing reports results for the three months ended September 30, 2021 and from inception on February 25, 2021 through September 30, 2021.
Financial and operating highlights
| Metric | Reported amount or status |
|---|---|
| Revenue | None; the company expected no operating revenue before a business combination. |
| Operating costs | $255,532 for Q3; $260,857 from inception. |
| Net loss | $252,490 for Q3; $257,815 from inception. Basic and diluted loss per share was $0.01 for Q3 and $0.02 from inception for both share classes. |
| Cash flow | $1,136,208 used in operating activities from inception; $251,678,512 provided by financing; $250,000,000 used to fund the trust account. |
| Cash and liquidity | $542,304 cash outside the trust account; $250,003,042 in trust investments; working capital of $1,384,477. |
| Debt and obligations | No long-term debt reported. Current liabilities were $55,138, including $38,178 of related-party advances. A $7,700,000 deferred underwriting fee is payable only if a business combination is completed. |
| Margins | Not meaningful: the company had no operating revenue. |
Changes, outlook, and risks
- Prior-period comparison: No prior-year comparable quarter is presented; the company was incorporated in February 2021 and completed its IPO in July 2021.
- Restatement: The company reclassified all 25 million redeemable public shares to temporary equity. The filing states the restatement did not change total assets, liabilities, or operating results, but it materially changed the presentation of equity and accumulated deficit.
- Controls: Management reported a material weakness in internal control over financial reporting related to accounting for complex financial instruments. Disclosure controls were deemed ineffective. Planned remediation included enhanced accounting research resources and communication; management gave no assurance the steps would be effective.
- Going concern and funding: Management said limited cash outside the trust account and uncertainty about obtaining additional financing raised substantial doubt about the company’s ability to continue as a going concern for one year from issuance. Sponsor and other related parties could lend funds but were not obligated to do so.
- SPAC timeline and contingencies: The company had until July 2, 2023 to complete a business combination, subject to any approved extension. If none is completed, public shares are to be redeemed under the stated terms. The sponsor’s trust indemnity may be limited by its ability to pay. COVID-19 could adversely affect the company or its target search, but the impact was not determinable.
- Other items: The company reported no legal proceedings, no off-balance-sheet arrangements, and no material subsequent events. No operating guidance was provided.
Important facts for investors to verify
- Confirm the issuer: this source identifies Social Capital Suvretta Holdings Corp. III, not ProKidney Corp.
- Review the restatement’s accounting and its effect on temporary equity, permanent deficit, and future reporting.
- Track remediation of the material weakness and whether controls are later assessed as effective.
- Assess the sufficiency of cash outside the trust account and the availability of any additional working-capital financing.
- Verify business-combination progress, redemption terms, and the applicable deadline or any extension.